SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last issued its earnings results on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $0.98 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Price Performance

SCYX stock opened at $1.04 on Tuesday. SCYNEXIS has a 12 month low of $0.82 and a 12 month high of $3.07. The firm’s 50-day moving average is $1.06 and its 200 day moving average is $1.23. The company has a market capitalization of $40.54 million, a PE ratio of -1.41 and a beta of 1.67.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered SCYNEXIS from a “hold” rating to a “sell” rating in a report on Saturday.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.